Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
572 studies found for:    Open Studies | "Leukemia, Myeloid, Acute"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Leukemia, Myeloid, Acute"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting ChEmo-Genomics Based Treatment of Acute Myeloid Leukemia
Condition: Leukemia, Myeloid, Acute
Interventions: Procedure: Tumor sampling;   Biological: Constiutional DNA sampling
2 Recruiting Molecular Imaging to Capture Disease Heterogeneity in Acute Myeloid Leukemia
Condition: Leukemia, Myeloid, Acute
Intervention: Procedure: FDG-PET/CT guided bone marrow sampling
3 Recruiting A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Condition: Leukemia, Myeloid, Acute
Intervention: Drug: CC-90009
4 Recruiting Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation
Condition: Leukemia, Myeloid, Acute
Intervention: Drug: Quizartinib
5 Recruiting A Safety and Efficacy Study of Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus Subcutaneous Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML)
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: AG-120;   Drug: Azacitidine;   Drug: AG-221
6 Recruiting Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: 300 mg Oral Azacitidine;   Drug: Placebo
7 Recruiting A Study of Safety, Efficacy and Pharmacodynamics of Azacitidine in Children and Young Adults With Acute Myeloid Leukemia.
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: Azacitidine;   Other: Control Arm
8 Recruiting Haematopoietic Stem Cell Transplantation (HSCT) in Comparison to Conventional Consolidation Therapy for Patients With Acute Myeloid Leukemia (AML) (Intermediate Risk) <= 60y. After First CR
Condition: Leukemia, Myeloid, Acute
Interventions: Biological: Human Stem Cell Transplantation;   Drug: Consolidation chemotherapy, i.e. High-dose Cytarabine (HiDAC)
9 Recruiting Safety and Efficacy Study of Idarubicin Dose Intensification to Treat Acute Myeloid Leukemia
Condition: Leukemia, Myeloid, Acute
Intervention: Drug: Idarubicin
10 Recruiting A Study to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: Decitabine;   Drug: BI 836858
11 Not yet recruiting BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML)
Condition: Leukemia, Myeloid, Acute
Intervention: Drug: BAY1436032
12 Recruiting BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients in Complete Remission With High Risk to Relapse
Condition: Leukemia, Myeloid, Acute
Intervention: Drug: BI 836858
13 Recruiting A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: Cobimetinib;   Drug: Idasanutlin;   Drug: Venetoclax
14 Recruiting A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)
Condition: Leukemia, Myeloid, Acute
Interventions: Biological: PNK-007;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Human recombinant Interleukin-2 (rhIL-2)
15 Recruiting PreventiOn of DYSbioSis Complications With Autologous Fecal Microbiota Transplantation in acutE myEloid Leukemia Patients Undergoing Intensive Treatment
Condition: Leukemia, Myeloid, Acute
Intervention: Drug: Autologous Fecal Microbiota Transplantation
16 Recruiting Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Condition: Leukemia, Myeloid, Acute
Intervention: Drug: JNJ-63709178
17 Recruiting Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Interventions: Drug: Azacitadine;   Drug: Fludarabine;   Drug: Cytarabine;   Drug: Lenograstim;   Drug: Filgastrim
18 Not yet recruiting Interleukin-21 (IL-21)- Expanded Natural Killer Cells for Induction of Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Intervention: Biological: NK Cells + Chemotherapy Starting
19 Recruiting Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Interventions: Drug: guadecitabine;   Drug: Treatment Choice (TC)
20 Not yet recruiting A Collaborative Palliative and Oncology Care Model for Patients With Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Interventions: Other: Standard Leukemia Care;   Other: Palliative Care

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.